Discover Grünenthal

1/23/2018

Aachen, Germany, October 30, 2017 – The Grünenthal Group announced today that the company renewed its syndicated loan facility on October 20, 2017. For the next five years, the company can access € 400 million of available loan granted by a bank consortium. In the course of the renewal the Grünenthal Group was able to achieve significantly improved terms and conditions, including lower loan margins. This syndicated loan facility is an essential pillar of the company’s financing strategy, which also includes the recently issued promissory note (Schuldscheindarlehen).

11/16/2017

Aachen, Germany, November 16, 2017 – Many patients who suffer strong or persistent pain receive inadequate relief from therapy. Improving pharmacotherapy and management for refractory pain is a so enormously complex problem that only concerted approaches which link together groups with different relevant expertise are likely to have success in discovering and developing novel and effective analgesics.

9/7/2017

Copenhagen, 7 September, 2017. Significant unmet medical needs in the field of pain in Europe have made pain research more relevant than ever. On the occasion of the congress of the European Pain Federation EFIC®, young scientists from across Europe presented the results of their pain research projects, which focus on novel ideas with the potential for achieving major advances in pain Management.

9/1/2017

Aachen, Germany, September 1, 2017. The Grünenthal Group today announces that Mark Fladrich has taken office as new Chief Commercial Officer (CCO). Grünenthal is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation headquartered in Aachen, Germany. In his last appointment Mark Fladrich served as Area Vice President, Southern and Western Europe for AstraZeneca.

8/28/2017

Aachen, Germany, 28. August 2017. Grünenthal GmbH issued a promissory note at the end of July 2017. The transaction was announced with a volume of € 150 million. Due to the strong interest of investors and the subsequent oversubscription, the initial transaction volume has been well exceeded and increased to € 300 million. Grünenthal diversifies its lenders and increases its lender base with the promissory note.

7/5/2017

The new research project NGN-PET was launched in the framework of the Innovative Medicine Initiative (IMI), the largest public-private partnership (PPP) for health research worldwide co-funded by the EU and the European pharmaceutical industry. The NGN-PET consortium unites the expertise and knowledge of industry partners from the European Federation of Pharmaceutical Industries and Associations (EFPIA), small and medium-sized enterprises (SMEs) and academia.

6/7/2017

Aachen, June 07, 2017 - The Grünenthal Group today announced that it has entered into an agreement with AstraZeneca for the global rights to Zomig® (Zolmitriptan) excluding Japan. Zomig® is indicated for the acute treatment of migraines and cluster headaches. The transaction is expected to be completed before the end of the second quarter of 2017, subject to regulatory clearances.

5/29/2017

Aachen, Germany, May 29, 2017. The Grünenthal Group, an R&D-driven, privately held international pharmaceutical company with headquarters in Aachen Germany, announced today that it has received the renowned Red Dot Product Design Award in the category life sciences and medicine for an innovative system for post-operative pain management. The “Red Dot” is given for good design and innovation. Patients are able to self-administer a pain drug using this system. The product has been available to patients in Western Europe since the first half of 2016.

Florian Dieckmann Head Global Communication

Florian Dieckmann

Head Global Communication


Grünenthal GmbH

52099 Aachen


E-Mail Florian.Dieckmann@grunenthal.com

Fabia Kehren, Head External Communications and Editorial Management

Fabia Kehren

Head of External Communication


Grünenthal GmbH

52099 Aachen


Phone +49 241 569-3269

E-Mail Fabia.Kehren@grunenthal.com